Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Infliximab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2016 Biomarkers information updated
- 14 Oct 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 16 Aug 2005 New trial record.